Aigner_Andreas Posted - 13 hours ago

TF SELL $SNDX at 20.74 : 21.17 SmallCap 98% Shp 1.78 S 2.48 N 0.87 RSI 37.39% SRSI 0% ADXR 13.26 #stocks #trading #finance #market

Aigner_Andreas Posted - 1 day ago

TD BUY $SNDX at 21.28, Supp 21.28 Resis 23.80 R12 HiLo 75% T1Y 31 buy 1.7 DIV N/A #Syndax Pha #stocks #trading #finance #market

Jonita Posted - 1 week ago

$SNDX in in in

Stock_Titan Posted - 1 week ago

$SNDX Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum https://www.stocktitan.net/news/SNDX/syndax-announces-participation-at-the-stifel-2024-virtual-targeted-p4wcarg28p6s.html

Omacrone Posted - 1 week ago

$CYBN still holding over 30k shares and have not sold a lick. It’s either 4-10 dollars or nothing baby! I will be dabbling in $SNDX for a bit though. That product seems promising too.

OpenOutcrier Posted - 1 week ago

$SNDX (+5.3% pre) Syndax Pharmaceuticals (SNDX) Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session - SI https://ooc.bz/l/29724

DonCorleone77 Posted - 1 week ago

$SNDX 4 of 4 - Syndax presents 'positive' results from AUGMENT-101 trial of Revumenib ....Revumenib was well-tolerated, and the safety profile was consistent with the Company's previously reported data. In the safety-evaluable patient population, Grade 3 or greater treatment-related adverse events that occurred in greater than 10% of patients included febrile neutropenia (13%; 3/23) and decreased neutrophil count (13%; 3/23). Grade 3 or greater differentiation syndrome was observed in 9% (2/23) of patients and Grade 3 QTc prolongation was observed in 4% (1/23) of patients. No treatment-related discontinuations or dose reductions due to adverse events occurred in the trial.

DonCorleone77 Posted - 1 week ago

$SNDX 3 of 4 - Syndax presents 'positive' results from AUGMENT-101 trial of Revumenib ....In this population, the complete remission or CR with partial hematological recovery rate was 23% (3/13; 95% CI: 5.0, 53.8), with a median time to CR or CRh of 2.3 months (95% CI: 1.0, 3.9). The overall response rate1 was 46% (6/13), and the composite response rate2 (CRc) was 39% (5/13). Sixty percent (3/5) of CRc patients achieved minimal residual disease negative status. The median overall survival was 6.9 months (95% CI, 2.3-not reached). Four (67%) of the 6 patients who achieved an overall response underwent HSCT, two of whom did not achieve a CR or CRh prior to transplant. Half (2/4) of the patients who underwent HSCT received post-transplant maintenance with revumenib and had been in remission for 6 and 9 months at the time of the July 24, 2023 data cutoff....

DonCorleone77 Posted - 1 week ago

$SNDX 2 of 4 - Syndax presents 'positive' results from AUGMENT-101 trial of Revumenib ...."As the only menin inhibitor with a formulation designed for the pediatric setting, we have an ongoing commitment to bringing this first- and best-in-class therapeutic agent to this important patient population in need of effective treatments." The presented data include efficacy and safety findings for pediatric patients with R/R KMT2Ar acute leukemia from the pivotal Phase 2 portion of the AUGMENT-101 study. Of the 57 patients enrolled in AUGMENT-101 with central confirmation of their KMT2Ar status and sufficient follow-up to be included in the efficacy-evaluable population, 13 (23%) were less than 18 years old with a median age of 5 years. The pediatric patients were heavily pretreated with a median of 4 prior lines of therapy including 8 (62%) that received prior venetoclax, 2 (15%) that received CAR-T and 6 (46%) that received prior hematopoietic stem cell transplant....

DonCorleone77 Posted - 1 week ago

$SNDX 1 of 4 - Syndax presents 'positive' results from AUGMENT-101 trial of Revumenib Syndax Pharmaceuticals announced the presentation of positive data from the pivotal AUGMENT-101 trial in pediatric patients with relapsed/refractory KMT2A-rearranged acute myeloid leukemia and acute lymphoid leukemia treated with revumenib, a first-in-class menin inhibitor. The pediatric data was featured in a Plenary Session titled "Pivotal Phase 2 Results of AUGMENT-101 for Revumenib in KMT2Ar Acute Leukemia: Pediatric Experience" at the 2024 American Society of Pediatric Hematology/Oncology Conference held April 3 - 6, 2024 in Seattle, Washington. "We are pleased to present positive results from pediatric patients treated with revumenib in the AUGMENT-101 pivotal trial demonstrating impressive activity and consistency with the adult population," said Neil Gallagher, M.D., Ph.D., President, Head of Research and Development at Syndax....

Stock_Titan Posted - 1 week ago

$SNDX Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session https://www.stocktitan.net/news/SNDX/syndax-presents-positive-pediatric-data-from-pivotal-augment-101-3wi2u7i04vvt.html

tedevan Posted - 1 week ago

$SNDX $BPMC $IOVA $SWTX $IMCR

Night_Owl_Biotech Posted - 1 week ago

With Morgan Stanley in the news again about M&A & bio valuations with rate cuts, attached is a list of all of the commercial-stage oncology focused bios that have been acquired or merged/spun-off showing the # of months the LLE took place after its last FDA approval (sorted low to high). On the right side please find the remaining independent commercial-stage oncology focused biopharmas noting how long it has been since FDA approval. Be careful, our date info may not be perfect with those that have/had multiple FDA approvals. If commercial-stage oncology focused M&A is expected to be hot this year (versus clinical-stage) then it appears there are only so many with market caps of less than $10B & a recent approval (enough to drive significant growth to an acquirer). Obvious candidates would be $SWTX $IOVA $IMCR $SNDX & $BPMC

Stock_Titan Posted - 1 week ago

$SNDX Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) https://www.stocktitan.net/news/SNDX/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-gjx1n299zxxi.html

jewell69 Posted - 2 weeks ago

$SNDX feels nice 2 b liked. woman touted it 4/3 on cnbc. day traded it. UN POCO A POCO 04/04/2024 13:37:48 Bought 113 SNDX @ 23.45 -2,649.85 0.00 0.00 04/03/2024 14:24:43 Sold 112 SNDX @ 23.92 2,679.00 0.00 0.04 04/01/2024 15:15:07 Bought 112 SNDX @ 23.84 -2,670.08 0.00 0.00 03/28/2024 10:23:34 Sold 111 SNDX @ 22.95 2,547.41 0.00 0.04 03/22/2024 15:24:44 Bought 111 SNDX @ 22.68 -2,517.48

commoncentsinvestor Posted - 2 weeks ago

$SNDX ONE TO CHECK OUT FOR BIG GAINS IN 2024 Anyone looking for a stock that could have a big increase in share price in 2024 might want to take a look at CVRX. They got FDA approval for its Barostim product to improve the lives of people suffering from heart failure back in 2019. They have spent the last 4 years building a market for their product and it is about to reap big rewards. They have been increasing their revenues, the number of implant centers, their territories, , and their public visibility by leaps and bounds and work on 84% gross margins. This should all result in big increases in revenues and share price this year. I expect a minimum of $65M in 2024 revenues and with 84% Gross Margins, a 15 times Market Cap would be very reasonable. That would put the share price at about $47. Current Share Price is under $18. With only 600 followers on Stock Twits, it is very early in the game for folks who like to invest in under followed small companies with HUGE potential.

Doozio Posted - 2 weeks ago

$SNDX huckleberries n $$$ patterns into 2025 during 🧠⏰♾️

huggenberg Posted - 2 weeks ago

$IBRX $SNDX A new paper on Entinostat in combination with Anktiva is out for a poster session at the American Association for Cancer Research (AACR). Entinostat is an HDAC Inhibitor from Syndax. Anktiva (N-803) is the IL-15 superagonist from ImmunityBio. https://www.abstractsonline.com/pp8/#!/20272/presentation/6249 I already wrote about the combo last week. https://stocktwits.com/huggenberg/message/567514384

DonCorleone77 Posted - 03/28/24

$SNDX Syndax completes enrollment in AUGMENT-101 trial Syndax Pharmaceuticals announced completion of enrollment in the AUGMENT-101 pivotal trial cohort of patients with relapsed/refractory mutant nucleophosmin acute myeloid leukemia. Topline data is expected in the fourth quarter of 2024 and could support a supplemental New Drug Application filing for revumenib in R/R mNPM1 AML in the first half of 2025. "We are thrilled to announce that we are one step closer to potentially expanding the therapeutic reach of revumenib in genetically defined acute leukemias," said Neil Gallagher, M.D., Ph.D., President, Head of Research and Development at Syndax. "We look forward to reporting topline data for this pivotal cohort in the fourth quarter of this year, which will follow closely behind a potential first approval of KMT2A acute leukemia in the third quarter."

Stock_Titan Posted - 03/28/24

$SNDX Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia https://www.stocktitan.net/news/SNDX/syndax-announces-completion-of-enrollment-in-augment-101-pivotal-zhkddpnxnaf2.html

GPS_OS_21_vs_SOC_5 Posted - 03/27/24

$SLS mcap $54M and this is the secondary asset - - $kura achieved a top line orr of 40% in an aml subset ph2 trial, $1.67b mcap -- SLS009 achieved a top line orr of 50% in AML mainline ph2 trial, $0.054b mcap -- SLS009 achieved 100% orr in the biomarker positive, end stage dying aml patients. -- dr's kadia and zeidner were clear, 009 only needed a 25% orr to become the standard of care for this setting. -- $SNDX Just Hit its Goal of 23% CR ... 009 is at 100% for biomarker Positive - hence the short n distort team https://finance.yahoo.com/news/syndax-announces-fda-priority-review-200500747.html

huggenberg Posted - 03/27/24

$SNDX PDUFA date for Revumenib is now set to September 26, 2024. For Axatilimab, which will be co-commercialized in the U.S. with $INCY, the PDUFA date is set one month earlier to August 28, 2024. It's time to evaluate a partnership for SNDX's Entinostat, an HDAC inhibitor in solid tumors. Studies showed it would work fine with $IBRX Anktiva, an IL15 Superagonist, with a PDUFA Date on April 24, 2024. The study with Entinostat and Anktiva: https://aacr.figshare.com/collections/Data_from_Cooperative_Immune-Mediated_Mechanisms_of_the_HDAC_Inhibitor_Entinostat_an_IL15_Superagonist_and_a_Cancer_Vaccine_Effectively_Synergize_as_a_Novel_Cancer_Therapy/6528504 Busy times for $SNDX, $INCY and $IBRX

fda_tracker Posted - 03/27/24

$SNDX New PDUFA Date 2024-09-26 Syndax Pharmaceuticals, Inc. Link:https://www.prnewswire.com/news-releases/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-relapsedrefractory-kmt2ar-acute-leukemia-302100145.html Calendar:http://www.fdatracker.com/fda-calendar/

Jarvis7424 Posted - 03/27/24

$SNDX more good news

DonCorleone77 Posted - 03/26/24

$SNDX Syndax granted Priority Review for NDA for revumenib by FDA Syndax Pharmaceuticals announced that the FDA has granted Priority Review for its New Drug Application, or NDA, for revumenib, the Company's first-in-class menin inhibitor, for the treatment of adult and pediatric relapsed or refractory, or R/R, KMT2A-rearranged, or KMT2Ar, acute leukemia. The NDA filing is being reviewed under the FDA's Real-Time Oncology Review Program, or RTOR, and has been assigned a Prescription Drug User Fee Act, or PDUFA, target action date of September 26, 2024. RTOR allows for a more efficient review and close engagement between the sponsor and the FDA throughout the submission process, which historically has led to earlier approvals. The NDA submission is supported by positive data from the pivotal AUGMENT-101 trial of revumenib in adult and pediatric patients with KMT2Ar acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL)....

Stock_Titan Posted - 03/26/24

$SNDX Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia https://www.stocktitan.net/news/SNDX/syndax-announces-fda-priority-review-of-nda-for-revumenib-for-the-6mls36342nmo.html

ccrock1533 Posted - 03/25/24

$SNDX Great investment, do you’re DD and realize it’s a 🚀

GPS_OS_21_vs_SOC_5 Posted - 03/19/24

@Bio_buyout m -- not sure if you were aware, venetoclax was approved based on P1 data, given the extremely high unmet need of the AML patients in 2018. - Very Similar to the venetoclax + aza refractory patients in the 009 TRIAL. - also, $KURA and $SNDX are both in registrational P2 Trials, for AML subset, and each are worth nearly $2B. That is Coming for 009. @DSCallez @NattyBumppo

TeresaTrades Posted - 03/19/24

Heavy options volume $TSEM $LICY $XP $SNDX $YUMC

GPS_OS_21_vs_SOC_5 Posted - 1 month ago

$SLS bio to clarify foe you, did you know Venetoclax was approved based on its Phase 1B trial results? Because of the dire unmet patient need - like th 009 pstients? 009 P2A trials are registrationally directed like the $SNDX and $KURA 2, companies worth nearly 2b based on their P2 assets. both their drugs, treat an aml subset.